Firicabtagene autoleucel (firi-cel) is a new treatment for people with a type of blood cancer called large B-cell lymphoma (LBCL). This study is for patients whose cancer has come back or hasn't responded to other treatments. Firi-cel is a type of gene therapy that uses the patient’s own immune cells, called T-cells, to fight the cancer. In this study, doctors will give one infusion (a special way to deliver medicine into the body) of firi-cel to the patients. They will then check if the treatment is safe and if it works.

To join, patients need to be at least 18 years old and have already tried other cancer treatments without success. They must live close to the treatment center for a month after the infusion to be monitored.

• This study involves a single infusion and up to 123 patients will be treated.
• Participants must stay near the treatment center for 4 weeks after receiving firi-cel.
• People with infections or other serious illnesses cannot join the study.

This study may offer hope for patients with relapsed or hard-to-treat LBCL.